DexCom EPS (Diluted) decreased by 23.9% to $0.51 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 88.9%, from $0.27 to $0.51. Over 3 years (FY 2022 to FY 2025), EPS (Diluted) shows an upward trend with a 37.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher values indicate stronger profitability even when accounting for potential share dilution.
Calculated by dividing net income by the weighted-average number of common shares outstanding, assuming the conversion o...
Used by all public companies to provide a realistic view of earnings per share for investors.
eps_diluted| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.19 | $0.21 | $0.23 | $0.12 | $0.24 | $0.22 | $0.12 | $0.28 | $0.29 | $0.61 | $0.36 | $0.35 | $0.34 | $0.38 | $0.27 | $0.45 | $0.70 | $0.67 | $0.51 |
| QoQ Change | — | +10.5% | +9.5% | -47.8% | +100.0% | -8.3% | -45.5% | +133.3% | +3.6% | +110.3% | -41.0% | -2.8% | -2.9% | +11.8% | -28.9% | +66.7% | +55.6% | -4.3% | -23.9% |
| YoY Change | — | — | — | -36.8% | +14.3% | — | -47.8% | +133.3% | +20.8% | +177.3% | +200.0% | +25.0% | +17.2% | -37.7% | -25.0% | +28.6% | +105.9% | +76.3% | +88.9% |